Rhupus Syndrome and Efficacy of Etanercept Treatment

Y

Yang Beibei

Status

Completed

Conditions

Rhupus Syndrome, Etanercept

Treatments

Drug: etanercept

Study type

Observational

Funder types

Other

Identifiers

NCT02766439
201233-004

Details and patient eligibility

About

between March 2013 and March 2014, Rhupus patients were enrolled to receive a 25-mg etanercept injection subcutaneously twice a week. The follow-up time of the study was 24 weeks.

Full description

between March 2013 and March 2014, patients who were unresponsive to therapy with corticosteroid and disease-modifying antirheumatic drugs (DMARDs), with a Disease Activity Score in 28 Joints (DAS28) >5.1 were enrolled to receive a 25-mg etanercept injection subcutaneously twice a week. The follow-up time of the study was 24 weeks.

Enrollment

6 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

- Rhupus patients who were unresponsive to therapy with corticosteroid and disease-modifying antirheumatic drugs (DMARDs), with a Disease Activity Score in 28 Joints (DAS28) >5.1

Exclusion criteria

- those who had participated in other studies

Trial design

6 participants in 1 patient group

Rhupus syndrome, SLE without RA
Description:
Rhupus syndrome, SLE without RA
Treatment:
Drug: etanercept

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems